News for Tempus AI Inc (TEM)

Shares of TempusAI Inc (TEM) experienced a 1.99% increase, gaining $1.33 to reach approximately $68.28. The options market showed heightened activity, with 75,0

Whales with a lot of money to spend have taken a noticeably bullish stance on Tempus AI. Looking at options history for Tempus AI TEM we detected 12 trades. I...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (”œTempus” or the ”œCompany”

PR NewswireNEW YORK, June 10, 2025 ARCX and UPSX offer 2X Daily Exposure to two captivating growth storiesNEW YORK, June 10, 2025 /PRNewswire/ -- Tradr ETF

TempusAIInc (TEM) shares experienced a slight decline, decreasing by $0.20 to approximately $61.88. Despite this, the options market showed relatively low activ

Founded in 2008, Caris specializes in precision oncology and helps diagnose cancer through its tumor profiling and blood-based cancer diagnostics. The company, whose rivals include Roche's Foundation Medicine, Guardant Health, and Grail, generates a majority of its revenue from its tissue-based molecular profiling which helps select the appropriate cancer therapy. In 2021, Caris raised $830 million at a $7.83 billion valuation in a Sixth Street-led funding round.

NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claim

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for healthcare applications. Read more on TEM.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (”œTempus” or the ”œCompany”

Market Analysis by covering: Alphabet Inc Class A, Applied Materials Inc, Amazon.com Inc, NVIDIA Corporation. Read 's Market Analysis on Investing.com

Financial giants have made a conspicuous bullish move on Tempus AI. Our analysis of options history for Tempus AI TEM revealed 31 unusual trades. Delving into ...

We recently published a list of These 10 Stocks Blew Past Expectations.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top-performing stocks on Monday. Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece […]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (”œTempus” or the ”œCompany”

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claim

TempusAI (TEM) recently experienced a 16% decline in its share price, largely attributed to a short report issued by Spruce Point. According to an analyst from

TempusAI (TEM) is witnessing a notable increase in bullish option activity, with a significant 38,181 call options traded, doubling the anticipated volume. The

Summary Tempus AI Inc (TEM), a leader in AI-driven precision medicine, announced the launch of xM for treatment response monitoring (TRM), a liquid biopsy assay